SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Aug 15 3:35 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (906)12/1/1997 3:53:00 PM
From: Pancho Villa  Read Replies (2) of 1359
 
Neuro you said: >>However,Janssen pulled its drug from AC consideration because its data was so weak, they are now conducting a very large supplemental Ph III. This took the time pressure off IPIC. Keep in mind that October would have been a monumental task to complete,with some risk of missing something....officially IPIC has always said it aimed to file by year-end, and they have taken a little extra time to make sure there are no loopholes or flaws, that their NDA file ...I would not be surprised to have the filing within the next two weeks. NeuroInvestment<<

Correct me if I am mistaken but one of the reasons for the delay may be that IPIC is also running extra studies on citicoline as the latest phase III results were weak and inconclusive (Some rather creative a posteriori interpretation/manipulation of results was need to report some positive news on inconclusive data - this is discussed in some of my earlier posts).

IMO, IPIC is under a scenario similar to Janssen's, with citicoline also being a weak drug. You see unfortunately stroke is a very challenging condition to treat effectively. The evidence so far is that several expensive drugs tested have not been found to be any more effective than inexpensive generic drugs [which are not very effective either!]. If we had any MD's in this thread [I am not one] perhaps they could enlighten the groupin this area.

Pancho

PS: I take it that the detailed information on IPIC's rationale and strategic thinking you provide comes from their PR department and that you are getting it in your role as analyst/investor/letter writer. In the event you were to be a spokesperson for IPIC, that is fine with me but IMO this is something you should disclose to the group.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext